News

Anupam Rasayan India Ltd share price gained 0.21% to Rs 1206.6 after the company`s net profit slipped by 8.54% to Rs 51.22 crore, while revenue from operations improved marginally 3.02% to Rs 654.98 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.11 lakh crore, expanding by 15.03%. It has inched up 1% over last one week and climbed by 13.02% in last one month while the market capitalization of Anupam Rasayan India Ltd has softened by 0.42% and 12.37% in the same period respectively. Profit before tax (PBT) of Anupam Rasayan India Ltd stood at Rs 69.68 crore in Q2 FY26, rising by 10.87% year-on-year, and jumping 24.27% quarter-on-quarter. EBITDA came in at Rs 150 crore, rallying 25.49% YoY and heading higher 11.86% sequentially. Total expenses saw a slight increase of 1.39% to Rs 548.67 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 353.89 crore, slightly declining by 8.26% YoY, while employee benefits expense was at Rs 64.88 crore, soaring 110.51% YoY. For the TTM ended FY26, revenue from operations declined slightly by 2.58% to Rs 1436.97 crore, while net profit softened by 4.46% to Rs 159.97 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 37199% to Rs 389.39 crore, and PBT contracted 18.17% to Rs 197.85 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 30.13 crore in FY26, as against Rs 59.03 crore in FY25. Anupam Rasayan India Ltd headed higher 5.06% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.05% during the same period.

Anupam Rasayan India Limited announced the appointment of Mr. Ravi Desai as Chief Operating Officer, effective August 14, 2026, while he continues as a Key Managerial Personnel. Previously, Mr. Desai held the position of Sales Head at Anupam Rasayan India Limited and possesses over 20 years of experience in the speciality chemicals industry.

Anupam Rasayan India announced that it has signed a non-binding Letter of Intent (LOI) with BASQUEVOLT, S.A., a European developer of solid-state lithium batteries, headquartered in Mi�ano (Araba/�lava), Spain. Under the LOI, the parties intend to explore the potential supply of a specialty chemical product over a period of up to 10 years for cumulative revenue of $300 Mn. The LOI is non-binding and preliminary. Any supply would be subject to the successful completion of product development and to the negotiation and signing of a definitive supply agreement.

Anupam Rasayan India (ARIL) has received credit ratings for bank facilities (Rs 1620 crore) and non-convertible debentures (Rs 160 crore) at CRISIL A+/ CRISIL A1. These ratings are placed on `Rating Watch with Developing Implications`. The ratings have been placed on watch following announcement by ARIL of acquisition of 43.3-48.2% equity stake in Bliss GVS Pharma, a pharmaceutical (pharma) formulations company based in India, which may be funded through debt, equity or internal accrual.

Anupam Rasayan India announced that the Board of Directors of the Company at its meeting held on 23 May 2026, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 15%) , subject to the approval of the shareholders.